Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Immunotherapy

Experimental ERAP1 Inhibitor Plus Immunotherapy Shrinks Tumours in Early Trial

Blocking the ERAP1 enzyme appears to unmask tumours to T cells, a change that could restore immunotherapy responses if larger trials confirm the effect and safety.

12 ARTICLES

4w ago

Ivonescimab Extends Survival in China Phase 3 Trial for Squamous Lung Cancer

3 ARTICLES

4w ago

Phase 1 TCER IMA401 Shows Early Safety and Tumor Responses in Solid Cancers

3 ARTICLES

4w ago

NEJM Paper Shows Zanidatamab Triplet Extends Survival Over Trastuzumab in First‑Line HER2+ Gastroesophageal Cancer

5 ARTICLES

2mo ago

Merck Reports Q1 Loss From Cidara Charge as Sales Beat and 2026 Outlook Rises

10 ARTICLES

2mo ago

FDA Rejects Replimune’s Melanoma Virus Therapy Again for Insufficient Evidence

8 ARTICLES

2mo ago

Securities Class Action Filed Against ImmunityBio After FDA Flags Anktiva Marketing

3 ARTICLES

4mo ago

Merck Beats Q4 Forecasts as 2026 Guidance Trails Estimates on Patent Losses

4 ARTICLES

5mo ago

Zydus Launches Low-Cost Nivolumab Biosimilar Tishtha in India After Court Greenlight

9 ARTICLES

5mo ago

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

4 ARTICLES

6mo ago

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

7 ARTICLES

6mo ago

Lead-Plaintiff Deadline Nears in MoonLake Securities Suits After SLK Trial Miss

6 ARTICLES

7mo ago

MoonLake Investors Get Deadline Reminder as Securities Suits Mount Over Sonelokimab Trial

7 ARTICLES

8mo ago

FDA Approves Libtayo as First Immunotherapy for Adjuvant Treatment of High‑Risk CSCC

8 ARTICLES

last yr.

Groundbreaking Lupus Treatment Trial Offers Hope for Drug-Free Remission

Immunotherapy

Experimental ERAP1 Inhibitor Plus Immunotherapy Shrinks Tumours in Early Trial

Ivonescimab Extends Survival in China Phase 3 Trial for Squamous Lung Cancer

Phase 1 TCER IMA401 Shows Early Safety and Tumor Responses in Solid Cancers

NEJM Paper Shows Zanidatamab Triplet Extends Survival Over Trastuzumab in First‑Line HER2+ Gastroesophageal Cancer

Merck Reports Q1 Loss From Cidara Charge as Sales Beat and 2026 Outlook Rises

FDA Rejects Replimune’s Melanoma Virus Therapy Again for Insufficient Evidence

Securities Class Action Filed Against ImmunityBio After FDA Flags Anktiva Marketing

Merck Beats Q4 Forecasts as 2026 Guidance Trails Estimates on Patent Losses

Zydus Launches Low-Cost Nivolumab Biosimilar Tishtha in India After Court Greenlight

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

Lead-Plaintiff Deadline Nears in MoonLake Securities Suits After SLK Trial Miss

MoonLake Investors Get Deadline Reminder as Securities Suits Mount Over Sonelokimab Trial

FDA Approves Libtayo as First Immunotherapy for Adjuvant Treatment of High‑Risk CSCC

Groundbreaking Lupus Treatment Trial Offers Hope for Drug-Free Remission

Never miss stories about

Immunotherapy